Aarti Pharmalabs Limited (AARTIPHARM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aarti Pharmalabs Limited (AARTIPHARM) has a cash flow conversion efficiency ratio of 0.022x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs362.80 Million ≈ $3.92 Million USD) by net assets (Rs16.58 Billion ≈ $179.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Aarti Pharmalabs Limited stock valuation for the company's overall valuation and market capitalisation.
Aarti Pharmalabs Limited - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Aarti Pharmalabs Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aarti Pharmalabs Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aarti Pharmalabs Limited ranked by their cash flow conversion efficiency. Explore AARTIPHARM cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhang Jia Jie Tourism Group Co Ltd
SHE:000430
|
0.022x |
|
Lincoln Educational Services
NASDAQ:LINC
|
0.218x |
|
Wushang Group Co Ltd
SHE:000501
|
0.033x |
|
Peapack-Gladstone Financial
NASDAQ:PGC
|
0.072x |
|
Qt Group Oyj
HE:QTCOM
|
0.064x |
|
Lloyds Banking Group PLC
LSE:LLOY
|
0.141x |
|
Fox Factory Holding Corp
NASDAQ:FOXF
|
0.005x |
|
Newonder Special Electric Co.Ltd
SHE:301120
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Aarti Pharmalabs Limited (2020–2025)
The table below shows the annual cash flow conversion efficiency of Aarti Pharmalabs Limited from 2020 to 2025. View Aarti Pharmalabs Limited share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs19.90 Billion ≈ $215.20 Million |
Rs3.32 Billion ≈ $35.86 Million |
0.167x | +35.32% |
| 2024-03-31 | Rs17.57 Billion ≈ $190.02 Million |
Rs2.16 Billion ≈ $23.40 Million |
0.123x | -27.03% |
| 2023-03-31 | Rs15.58 Billion ≈ $168.54 Million |
Rs2.63 Billion ≈ $28.44 Million |
0.169x | +635.36% |
| 2022-03-31 | Rs13.86 Billion ≈ $149.94 Million |
Rs-437.04 Million ≈ $-4.73 Million |
-0.032x | -- |
| 2021-03-31 | Rs2.27 Million ≈ $24.52K |
Rs0.00 ≈ $0.00 |
0.000x | -- |
| 2020-03-31 | Rs2.31 Million ≈ $25.02K |
Rs-186.75K ≈ $-2.02K |
-0.081x | -- |
About Aarti Pharmalabs Limited
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous sys… Read more